Bedell Frazier Investment Counselling LLC Makes New $618,000 Investment in Pfizer Inc. (NYSE:PFE)

Bedell Frazier Investment Counselling LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 23,281 shares of the biopharmaceutical company’s stock, valued at approximately $618,000.

Several other hedge funds also recently made changes to their positions in PFE. United Bank grew its holdings in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares during the last quarter. Fred Alger Management LLC increased its stake in Pfizer by 7.4% in the 3rd quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company’s stock worth $2,971,000 after purchasing an additional 7,076 shares in the last quarter. Tradition Wealth Management LLC increased its stake in Pfizer by 4.5% in the 3rd quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 1,099 shares in the last quarter. Bellevue Group AG lifted its stake in Pfizer by 59.2% during the third quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company’s stock valued at $4,083,000 after buying an additional 52,461 shares in the last quarter. Finally, Semmax Financial Advisors Inc. boosted its holdings in shares of Pfizer by 3.2% in the third quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company’s stock worth $2,695,000 after buying an additional 3,185 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.8 %

Pfizer stock opened at $25.20 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm’s fifty day simple moving average is $26.06 and its 200-day simple moving average is $26.90. The company has a market capitalization of $142.93 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.